HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.

Abstract
In a phase II study, daclizumab was given as single second-line agent to 62 patients with steroid-refractory acute graft-versus-host disease (aGVHD). Complete resolution of aGVHD was achieved in 68.8% of patients. This response rate was significantly associated with a lower number of involved organs and smaller extent of skin involvement. The 4-year event-free survival (EFS) was 54.6%. Grade > or =III aGVHD, > or =2 involved organs at baseline and patient age >18 years were independently associated with lower EFS. Daclizumab could be a suitable alternative treatment for aGVHD, particularly when limited to the skin or gastrointestinal tract.
AuthorsPierre Bordigoni, Sophie Dimicoli, Laurence Clement, Cédric Baumann, Alexandra Salmon, Francis Witz, Pierre Feugier
JournalBritish journal of haematology (Br J Haematol) Vol. 135 Issue 3 Pg. 382-5 (Nov 2006) ISSN: 0007-1048 [Print] England
PMID16984386 (Publication Type: Clinical Trial, Phase II, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Daclizumab
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Age Factors
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Child
  • Child, Preschool
  • Daclizumab
  • Female
  • Graft vs Host Disease (drug therapy, mortality, pathology)
  • Humans
  • Immunoglobulin G (adverse effects, therapeutic use)
  • Immunosuppressive Agents (adverse effects, therapeutic use)
  • Infant
  • Male
  • Middle Aged
  • Prospective Studies
  • Remission Induction
  • Stem Cell Transplantation (adverse effects)
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: